EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
Metrics: PDF 2855 views | HTML 6446 views | ?
Xueli Nan1,2, Chao Xie2, Xueyan Yu3 and Jie Liu2,4
1School of Medicine and Life Sciences, University of Ji’nan-Shandong Academy of Medical Sciences, Shandong, China
2Department of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong, China
3Department of Oncology, Shandong Provincial Chest Hospital, Shandong, China
4Shandong Academy of Medical Sciences, Shandong, China
Jie Liu, email: [email protected]
Keywords: EGFR TKI, first-line treatment, non-small-cell-lung cancer, EGFR mutations, combined therapy
Received: February 21, 2017 Accepted: July 26, 2017 Published: August 09, 2017
After the discovery of activating mutations in EGFR, EGFR tyrosine kinase inhibitors (TKIs) have been introduced into the first-line treatment of non-small-cell lung cancer (NSCLC). A series of studies have shown that EGFR TKI monotherapy as first-line treatment can benefit NSCLC patients harbouring EGFR mutations. Besides, combination strategies based on EGFR TKIs in the first line treatment have also been proved to delay the occurrence of resistance. In this review, we summarize the scientific literature and evidence of EGFR TKIs as first-line therapy from the first-generation EGFR TKIs to conceptually proposed fourth-generation EGFR TKI, and also recommend the application of monotherapy and combination therapies of the EGFR-based targeted therapy with other agents such as chemotherapy, anti-angiogenic drugs and immunecheckpoint inhibitors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.